Cinacalcet for the treatment of primary hyperparathyroidism
Hüsniye Başer1, Reyhan Ersoy2, Bekir Çakır2
1S.B. Ankara Atatürk Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Hastalıkları Kliniği, Bilkent, ANKARA
2Yıldırım Beyazıt Üniversitesi Tıp Fakültesi, İç Hastalıkları ABD, Bilkent, ANKARA
Parathyroidectomy is the only curative management of primary hyperparatyroidism (PHP). However there might be need for medical therapy when operation is unsuccessful, there are comorbid diseases which make the patient inoperable or when the patient does not want to be operated. Cinacalcet is a calcimimetic agent which is allosteric modulator of Ca sensing receptor (CaSR). Ca sensing receptors are localized on the surface of parathyroid cells and play a primary role in regulation of parathormone synthesis. Cinacalcet increases the sensitivity of CaSR for extracellular Ca concentration and decreases PTH secretion. In this letter the usage of cinacalcet in PHP is reviewed.